약물 용출 스텐트 시장 보고서 : 코팅, 약제, 스텐트 플랫폼, 세대, 용도, 최종 사용자, 지역별(2025-2033년)
Drug-Eluting Stents Market Report by Coating, Drug, Stent Platform, Generation, Application, End User, and Region 2025-2033
상품코드
:
1642474
리서치사
:
IMARC Group
발행일
:
2025년 01월
페이지 정보
:
영문 122 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
약물 용출 스텐트 세계 시장 규모는 2024년 88억 달러에 달했습니다. 향후 2033년까지 142억 달러에 달할 것으로 예측되며, 2025-2033년의 성장률(CAGR)은 5.23%를 나타낼 것으로 예상됩니다. 심혈관 질환의 유병률 증가가 시장을 견인하고 있습니다.
약물 용출 스텐트(DES)는 말초 동맥과 관상 동맥에서 약물을 느리게 방출하고 세포 증식을 차단하고 건강한 혈액 흐름을 촉진하는 데 사용되는 관상 동맥 장치입니다. DES는 금속 스텐트, 폴리머 코팅, 항 재협착제로 구성되어 있습니다. 스텐트에는 동맥을 원활하게 유지하고 충분한 혈류를 보장하기 위한 약제가 코팅되어 있습니다. DES는 심장 동맥의 폐색을 치료하고, 플라크의 축적과 혈전을 예방하고, 재관류를 줄이기 위해 널리 사용됩니다. 스텐트는 낮은 침습성(MI)이며, 재협착율이 낮고, 혈관의 치유가 촉진되고, 항혈소판 이중 요법의 필요성이 감소됩니다.
약물 용출 스텐트 시장 경향 :
만성 질환을 겪기 쉬운 노인 인구 증가는 시장 성장을 가속하는 중요한 요인 중 하나입니다. DES는 스텐트가 관상 동맥 우회 수술과 같은 침습적 치료의 필요성을 줄이는 데 도움이되므로 동맥 장애의 발병 위험이 높은 환자에게 널리 사용됩니다. 또한 대중의 건강에 해로운 다이어트 패턴, 운동 부족, 앉기 쉬운 생활 스타일로 인한 심혈관 질환의 유병률 증가는 시장 성장을 뒷받침하고 있습니다. 또한 생체 흡수성 스텐트 출시 등 다양한 기술의 진보가 시장 성장을 뒷받침하고 있습니다. 이 스텐트는 신체에서 쉽게 용해 가능하며 스텐트 혈전증의 발병 위험을 줄입니다. 이에 따라 폴리머가 없는 코팅을 한 스텐트의 보급이 시장 성장에 긍정적인 영향을 미치고 있습니다. 이 스텐트는 약물 충전 능력이 높고 약물 용출 속도가 빠릅니다. 그 밖의 요인으로는 비정상 심리듬, 심부전, 심근경색의 이환율 상승, 대중 간의 MI 기술에 대한 수요 증가 등을 들 수 있으며 시장 성장을 뒷받침할 것으로 예상되고 있습니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 약물 용출 스텐트 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 코팅별
제7장 시장 분석 : 약제별
- 시롤리무스
- 파클리탁셀
- 조탈롤리무스
- 에베롤리무스
- 바이올리무스
- 기타
제8장 시장 분석 : 스텐트 플랫폼별
- 스테인레스 스틸
- 코발트 크롬
- 플래티넘 크롬
- 니티놀
- 기타
제9장 시장 분석 : 세대별
제10장 시장 분석: 용도별
제11장 시장 내역: 최종 사용자별
제12장 시장 분석: 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제13장 SWOT 분석
제14장 밸류체인 분석
제15장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제16장 가격 분석
제17장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abbott Laboratories
- B. Braun Melsungen AG
- Biosensors International Group Ltd.
- Biotronik
- Boston Scientific Corporation
- Cardinal Health Inc.
- Cook Medical LLC(Cook Group Incorporated)
- Lepu Medical Technology(Beijing) Co. Ltd.
- Medtronic plc
- MicroPort Scientific Corporation
- Sino Medical Sciences Technology Inc.
- Terumo Corporation
SHW
영문 목차
The global drug-eluting stents market size reached USD 8.8 Billion in 2024. Looking forward, the market is expected to reach USD 14.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5.23% during 2025-2033. The increasing prevalence of cardiovascular diseases is propelling the market.
A drug-eluting stent (DES) is a coronary device that is used for the slow release of drugs in peripheral or coronary arteries to block cell proliferation and promote a healthy flow of blood. It consists of a metallic stent, polymer coating and anti-restenosis drug. The stent is coated with medications that assist the arteries to remain smooth and ensure adequate blood flow. DES is widely used to treat blockages in heart arteries, prevent plaque buildup, blood clots and reduce repeated revascularization. The stent is minimally invasive (MI) and offers lower restenosis rates, enhanced vessel healing and reduced need for prolonged dual antiplatelet therapy.
Drug-Eluting Stents Market Trends:
The rising geriatric population prone to chronic medical ailments is one of the key factors driving the growth of the market. DES is widely utilized in patients with a high risk of developing arterial disorders as the stents aid in reducing the need for invasive procedures, such as coronary artery bypass surgeries. Additionally, the increasing prevalence of cardiovascular diseases due to the unhealthy dietary patterns, lack of physical activity and sedentary lifestyles of the masses is favoring the market growth. Moreover, various technological advancements, such as the launch of bioresorbable stents, are providing a thrust to the market growth. These stents are easily dissolvable in the body and reduce the risk of developing stent thrombosis. In line with this, the widespread adoption of stents with polymer-free coatings is positively impacting the market growth. These stents exhibit a higher drug loading capacity and quicker drug-eluting rate. Other factors, including the rising incidence of abnormal heart rhythms, heart failure and heart attack disease, along with the increasing demand for MI techniques among the masses, are anticipated to drive the market toward growth.
Global Drug-Eluting Stents Industry Segmentation:
Breakup by Coating:
Polymer Based Coating
Polymer Free Coating
Breakup by Drug:
Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Biolimus
Others
Breakup by Stent Platform:
Stainless-steel
Cobalt-Chromium
Platinum-Chromium
Nitinol
Others
Breakup by Generation:
1st Generation
2nd Generation
3rd Generation
4th Generation
Breakup by Application:
Coronary Artery Disease
Peripheral Artery Disease
Breakup by End User:
Hospitals
Ambulatory Surgical Centers
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun Melsungen AG, Biosensors International Group Ltd., Biotronik, Boston Scientific Corporation, Cardinal Health Inc., Cook Medical LLC (Cook Group Incorporated), Lepu Medical Technology (Beijing) Co. Ltd., Medtronic plc, MicroPort Scientific Corporation, Sino Medical Sciences Technology Inc. and Terumo Corporation.
Key Questions Answered in This Report
- 1. What was the size of the global drug-eluting stents market in 2024?
- 2. What is the expected growth rate of the global drug-eluting stents market during 2025-2033?
- 3. What are the key factors driving the global drug-eluting stents market?
- 4. What has been the impact of COVID-19 on the global drug-eluting stents market?
- 5. What is the breakup of the global drug-eluting stents market based on the coating?
- 6. What is the breakup of the global drug-eluting stents market based on the stent platform?
- 7. What is the breakup of the global drug-eluting stents market based on application?
- 8. What is the breakup of the global drug-eluting stents market based on the end user?
- 9. What are the key regions in the global drug-eluting stents market?
- 10. Who are the key players/companies in the global drug-eluting stents market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Drug-Eluting Stents Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Coating
- 6.1 Polymer Based Coating
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Polymer Free Coating
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Drug
- 7.1 Sirolimus
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Paclitaxel
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Zotarolimus
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Everolimus
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Biolimus
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Stent Platform
- 8.1 Stainless-steel
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Cobalt-Chromium
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Platinum-Chromium
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Nitinol
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by Generation
- 9.1 1st Generation
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 2nd Generation
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 3rd Generation
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 4th Generation
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Application
- 10.1 Coronary Artery Disease
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Peripheral Artery Disease
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
11 Market Breakup by End User
- 11.1 Hospitals
- 11.1.1 Market Trends
- 11.1.2 Market Forecast
- 11.2 Ambulatory Surgical Centers
- 11.2.1 Market Trends
- 11.2.2 Market Forecast
- 11.3 Others
- 11.3.1 Market Trends
- 11.3.2 Market Forecast
12 Market Breakup by Region
- 12.1 North America
- 12.1.1 United States
- 12.1.1.1 Market Trends
- 12.1.1.2 Market Forecast
- 12.1.2 Canada
- 12.1.2.1 Market Trends
- 12.1.2.2 Market Forecast
- 12.2 Asia-Pacific
- 12.2.1 China
- 12.2.1.1 Market Trends
- 12.2.1.2 Market Forecast
- 12.2.2 Japan
- 12.2.2.1 Market Trends
- 12.2.2.2 Market Forecast
- 12.2.3 India
- 12.2.3.1 Market Trends
- 12.2.3.2 Market Forecast
- 12.2.4 South Korea
- 12.2.4.1 Market Trends
- 12.2.4.2 Market Forecast
- 12.2.5 Australia
- 12.2.5.1 Market Trends
- 12.2.5.2 Market Forecast
- 12.2.6 Indonesia
- 12.2.6.1 Market Trends
- 12.2.6.2 Market Forecast
- 12.2.7 Others
- 12.2.7.1 Market Trends
- 12.2.7.2 Market Forecast
- 12.3 Europe
- 12.3.1 Germany
- 12.3.1.1 Market Trends
- 12.3.1.2 Market Forecast
- 12.3.2 France
- 12.3.2.1 Market Trends
- 12.3.2.2 Market Forecast
- 12.3.3 United Kingdom
- 12.3.3.1 Market Trends
- 12.3.3.2 Market Forecast
- 12.3.4 Italy
- 12.3.4.1 Market Trends
- 12.3.4.2 Market Forecast
- 12.3.5 Spain
- 12.3.5.1 Market Trends
- 12.3.5.2 Market Forecast
- 12.3.6 Russia
- 12.3.6.1 Market Trends
- 12.3.6.2 Market Forecast
- 12.3.7 Others
- 12.3.7.1 Market Trends
- 12.3.7.2 Market Forecast
- 12.4 Latin America
- 12.4.1 Brazil
- 12.4.1.1 Market Trends
- 12.4.1.2 Market Forecast
- 12.4.2 Mexico
- 12.4.2.1 Market Trends
- 12.4.2.2 Market Forecast
- 12.4.3 Others
- 12.4.3.1 Market Trends
- 12.4.3.2 Market Forecast
- 12.5 Middle East and Africa
- 12.5.1 Market Trends
- 12.5.2 Market Breakup by Country
- 12.5.3 Market Forecast
13 SWOT Analysis
- 13.1 Overview
- 13.2 Strengths
- 13.3 Weaknesses
- 13.4 Opportunities
- 13.5 Threats
14 Value Chain Analysis
15 Porters Five Forces Analysis
- 15.1 Overview
- 15.2 Bargaining Power of Buyers
- 15.3 Bargaining Power of Suppliers
- 15.4 Degree of Competition
- 15.5 Threat of New Entrants
- 15.6 Threat of Substitutes
16 Price Analysis
17 Competitive Landscape
- 17.1 Market Structure
- 17.2 Key Players
- 17.3 Profiles of Key Players
- 17.3.1 Abbott Laboratories
- 17.3.1.1 Company Overview
- 17.3.1.2 Product Portfolio
- 17.3.1.3 Financials
- 17.3.1.4 SWOT Analysis
- 17.3.2 B. Braun Melsungen AG
- 17.3.2.1 Company Overview
- 17.3.2.2 Product Portfolio
- 17.3.2.3 SWOT Analysis
- 17.3.3 Biosensors International Group Ltd.
- 17.3.3.1 Company Overview
- 17.3.3.2 Product Portfolio
- 17.3.4 Biotronik
- 17.3.4.1 Company Overview
- 17.3.4.2 Product Portfolio
- 17.3.4.3 SWOT Analysis
- 17.3.5 Boston Scientific Corporation
- 17.3.5.1 Company Overview
- 17.3.5.2 Product Portfolio
- 17.3.5.3 Financials
- 17.3.5.4 SWOT Analysis
- 17.3.6 Cardinal Health Inc.
- 17.3.6.1 Company Overview
- 17.3.6.2 Product Portfolio
- 17.3.6.3 Financials
- 17.3.6.4 SWOT Analysis
- 17.3.7 Cook Medical LLC (Cook Group Incorporated)
- 17.3.7.1 Company Overview
- 17.3.7.2 Product Portfolio
- 17.3.7.3 SWOT Analysis
- 17.3.8 Lepu Medical Technology (Beijing) Co. Ltd.
- 17.3.8.1 Company Overview
- 17.3.8.2 Product Portfolio
- 17.3.8.3 Financials
- 17.3.9 Medtronic plc
- 17.3.9.1 Company Overview
- 17.3.9.2 Product Portfolio
- 17.3.9.3 Financials
- 17.3.9.4 SWOT Analysis
- 17.3.10 MicroPort Scientific Corporation
- 17.3.10.1 Company Overview
- 17.3.10.2 Product Portfolio
- 17.3.11 Sino Medical Sciences Technology Inc.
- 17.3.11.1 Company Overview
- 17.3.11.2 Product Portfolio
- 17.3.12 Terumo Corporation
- 17.3.12.1 Company Overview
- 17.3.12.2 Product Portfolio
- 17.3.12.3 Financials
- 17.3.12.4 SWOT Analysis
관련자료
